We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329511

CAS#: 1809249-37-3

Description: Remdesivir, also known as GS-5734, is a prodrug form of the antiviral nucleoside analog GS-44152. Upon entry into cells, remdesivir is metabolized into the nucleotide triphosphate GS-441524. Remdesivir inhibits murine hepatitis virus (MHV) with an EC50 of 30 nM, and blocks SARS-CoV and MERS-CoV in HAE cells with EC50s of both 74 nM in HAE cells after treatment for 24 h. GS-5734 inhibits both epidemic and zoonotic coronaviruses. It was developed as a treatment for filovirus infections such as Ebola virus disease and Marburg virus. Remdesivir is currently under trials COVID-19. ******* WARNING****** Our product Remdesivir is a Pure chemical in Powder form for laboratory research use only, NOT FOR HUMAN OR PATIENT USE

Price and Availability

Size Price Shipping out time Quantity
5mg USD 110 Same day
10mg USD 195 Same day
25mg USD 450 Same day
50mg USD 650 Same day
100mg USD 950 Same day
200mg USD 1650 Same day
500mg USD 2450 Same day
1g USD 3750 Same day
2g USD 5750 Same day
Inquire bulk and customized quantity

Pricing updated 2020-06-02. Prices are subject to change without notice.

Remdesivir, purity > 98%, is in stock. WARNING: Our product Remdesivir is a Pure chemical in Powder form for laboratory research use only. It is NOT a FDA approved medicine, and can NOT be used for any treatment or clinical trials on humans! Your order will NOT be fulfilled unless the order is coming from biotech, pharmaceutical-related business, academic or government institute!

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 329511
Name: Remdesivir
CAS#: 1809249-37-3
Chemical Formula: C27H35N6O8P
Exact Mass: 602.2254
Molecular Weight: 602.58
Elemental Analysis: C, 53.82; H, 5.85; N, 13.95; O, 21.24; P, 5.14

Synonym: Remdesivir; GS-5734; GS 5734; GS5734, Prodrug of GS-441524; Prodrug of GS441524; Prodrug of GS441524;

IUPAC/Chemical Name: 2-ethylbutyl ((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate


InChi Code: InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1

SMILES Code: C[C@H](N[P@@](OC1=CC=CC=C1)(OC[C@H]2O[C@@](C#N)(C3=CC=C4C(N)=NC=NN43)[C@H](O)[C@@H]2O)=O)C(OCC(CC)CC)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (SDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Additional Information

(1). formulation for in vivo study (Author from NIH):
....treated with 5 mg/kg remdesivir in vehicle solution (5 mg/mL 12% sulfobutylether-β-cyclodextrin in water and hydrochloric acid, pH3.5)

(2). formulation for in vivo study ( Author from CDC)
One group of animals received remdesivir (10 mg/kg) (Gilead Sciences) in vehicle solution [12% sulfobutylether-β-cyclodextrin in water and hydrochloric acid (pH 3.5)]


1: Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. 2020 Apr 10. doi: 10.1007/s10067-020-05073-9. Epub ahead of print. PMID: 32277367.

2: Kakodkar P, Kaka N, Baig MN. A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). Cureus. 2020 Apr 6;12(4):e7560. doi: 10.7759/cureus.7560. PMID: 32269893; PMCID: PMC7138423.

3: Cao YC, Deng QX, Dai SX. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Med Infect Dis. 2020 Apr 2:101647. doi: 10.1016/j.tmaid.2020.101647. Epub ahead of print. PMID: 32247927; PMCID: PMC7151266.

4: Xie M, Chen Q. Insight into 2019 novel coronavirus - an updated intrim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis. 2020 Apr 1. doi: 10.1016/j.ijid.2020.03.071. Epub ahead of print. PMID: 32247050; PMCID: PMC7118633.

5: Reina J. Remdesivir, la esperanza antiviral frente al SARS-CoV-2 [Remdesivir, the antiviral hope against SARS-CoV-2]. Rev Esp Quimioter. 2020 Apr 1:reina01apr2020. Spanish. doi: 10.37201/req/098.2020. Epub ahead of print. PMID: 32239125.

6: Amirian ES, Levy JK. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health. 2020 Mar 27;9:100128. doi: 10.1016/j.onehlt.2020.100128. PMID: 32258351; PMCID: PMC7125341.

7: Zhang C, Huang S, Zheng F, Dai Y. Controversial treatments: An updated understanding of the coronavirus disease 2019. J Med Virol. 2020 Mar 26. doi: 10.1002/jmv.25788. Epub ahead of print. PMID: 32219882.

8: McCreary EK, Pogue JM. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infect Dis. 2020 Mar 23;7(4):ofaa105. doi: 10.1093/ofid/ofaa105. PMID: 32284951; PMCID: PMC7144823.

9: Du B, Qiu HB, Zhan X, Wang YS, Kang HYJ, Li XY, Wang F, Sun B, Tong ZH. [Pharmacotherapeutics for the new coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):173-176. Chinese. doi: 10.3760/cma.j.issn.1001-0939.2020.03.005. PMID: 32164081.

10: Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020 Mar 9:AAC.00399-20. doi: 10.1128/AAC.00399-20. Epub ahead of print. PMID: 32152082.

11: Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, Ko WC, Hsueh PR. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 2020 Mar 4. doi: 10.1016/j.jmii.2020.02.012. Epub ahead of print. PMID: 32173241; PMCID: PMC7128959.

12: De Clercq E. New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. Chem Asian J. 2019 Nov 18;14(22):3962-3968. doi: 10.1002/asia.201900841. Epub 2019 Aug 7. PMID: 31389664.

13: Hoenen T, Groseth A, Feldmann H. Therapeutic strategies to target the Ebola virus life cycle. Nat Rev Microbiol. 2019 Oct;17(10):593-606. doi: 10.1038/s41579-019-0233-2. Epub 2019 Jul 24. PMID: 31341272.

14: Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019 Jul;167:45-67. doi: 10.1016/j.antiviral.2019.04.006. Epub 2019 Apr 8. PMID: 30974127; PMCID: PMC7132446.

15: Cardile AP, Warren TK, Martins KA, Reisler RB, Bavari S. Will There Be a Cure for Ebola? Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:329-348. doi: 10.1146/annurev-pharmtox-010716-105055. Epub 2016 Dec 7. PMID: 27959624.